Greetings. Welcome to the USANA Health Sciences' fourth quarter and fiscal year 2025 earnings call. At this time, all participants will be in listening only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, I'll now turn the conference over to Andrew Masuda, Director of Investor Relations. Thank you, Andrew. You may now begin.

Thanks, Robin. Good morning, everyone. We appreciate you joining us to review our fourth quarter and fiscal year 2025 results. Today's conference call is being broadcast live via webcast and can be accessed directly from our website at ir.usana.com. Shortly following the call, a replay will be available on our website. As a reminder, during the course of this conference call, management will make forward-looking statements regarding future events or the future financial performance of our company. Those statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from the results projected in such forward-looking statements. Examples of these statements include those regarding our strategies and outlook for fiscal year 2026, uncertainty related to the economic and operating environment around the world, and our operations and financial results. We caution you that these statements should be considered in conjunction with disclosures, including specific risk factors and financial data contained in our most recent filings with the SEC. I'm joined by our chairman and chief executive officer, Kevin Guest, our chief financial officer, Doug Hecking, our chief commercial officer, Brent Neidig, our chief operating officer, Walter Note, as well as other executives. Yesterday, after the market closed, we announced our fourth quarter in fiscal year 2025 results and posted our management commentary document on the company's website. We'll now hear brief remarks from Kevin and Doug before opening the call for questions.

Thank you, Andrew, and good morning, everyone. As we sharpen our strategic focus and position the company for renewed and sustainable growth, I'm honored to return as Chief Executive Officer while continuing to serve as Chairman of the Board. I appreciate the Board's confidence in my leadership and its commitment to ensuring continual stability and disciplined execution during this next phase of growth. As I reassume the role of CEO, I do so with a deep understanding of USANA's strengths and a clear view of the opportunities ahead, with the fruition of our strategic plans that we will execute. Having spent more than three decades at this company, including eight years as CEO, I have seen firsthand the power of our science-based products, the dedication of our employees, and the resilience of our sales force across the world. These elements form the core of USANA's competitive advantage and establish a solid foundation for the long-term value creation that we intend to deliver. During my previous tenure, USANA expanded its international footprint, strengthened operational capabilities, and achieved record financial results. While this external environment continues to evolve, our strategic pillars remain consistent. Scientific excellence at the center of product innovation, operational discipline and cost efficiency, a high-performing aligned global sales force, and a culture rooted in integrity, resilience, and execution. Over the past several weeks, I've engaged in extensive discussions with our leadership team as well as our brand partners. These conversations reinforce that USANA remains well-positioned with strong underlying fundamentals and meaningful opportunities for growth across multiple markets and channels. However, the clear message is that we must move with greater speed, focus, relevancy, and precision. As we look ahead, our priorities are straightforward. First, strengthen USANA's global brand positioning by delivering science-backed nutrition through an omni-channel platform and evolving the company's identity from a legacy direct selling business to a modern science-driven nutritional products company. Second, enhance the customer and brand partner experience to drive retention, loyalty, and long-term brand equity. Third, reinvigorate global sales momentum through enhanced field support, market-specific strategies, and strengthen leadership engagement. Fourth, advance our product innovation pipeline by leveraging our world-class research and science teams to deliver differentiated offerings. Fifth, improve operational efficiencies across the organization through disciplined cost management and streamlined processes. And sixth, execute with accountability at every level of the business, ensuring our actions translate into measurable, sustainable results. We are committed to delivering shareholder value by focusing on these top priorities. Importantly, our consolidated net sales outlook for fiscal 2026 is for growth of 4% at the midpoint, reflecting confidence in our strategy and our ability to execute. We will also remain focused on long-term strategic execution, not short-term optimization, as we strengthen the company for its next chapter of growth. Our fiscal 2026 operating strategy entails the following. First, expand our omni-channel reach by leveraging USANA's strong nutrition foundation and diversifying distribution channels to access a larger global base of health-conscious consumers and strengthen brand relevance. Second, advance product innovation through refreshed branding, alignment with modern consumer usage behaviors, and a robust pipeline for upgraded and new products launching globally in 2026. Third, accelerate technology modernization by adopting best-in-practice third-party platforms to improve customer experience, enable scalable growth, and drive long-term IT and operational efficiencies. Fourth, drive highest growth through continued direct-to-consumer expansion, new channel and product launches, and entering into additional markets. We are also leveraging USANA's capabilities to improve margins, including transitioning to in-house manufacturing to increase speed, efficiency, and reduce costs. Fifth, scale rise wellness performance by building on the strong recent momentum, expanding the rise bar footprint and accelerating protein pots distribution particularly within major retailers and within club retail channels USANA's mission culture and people have always been at the heart of our success as we embark on this transition I am confident in our direction and energized by the opportunities ahead together with clarity discipline and a shared vision we will position USANA to deliver stronger performance and create enduring value for all stakeholders. With that, I'll now ask Doug to provide additional color on our fiscal 2026 outlook.

Thanks, Kevin, and good morning, everyone. I'd like to provide some additional color on our fiscal 2026 outlook and the key financial considerations shaping our guidance for the upcoming year. As Kevin mentioned, we're expecting net sales growth at the midpoint of about 4%. The sales growth is being driven by our venture companies, Rise Wellness and Haya. Note that our outlook reflects a 52-week fiscal year in 2026, which includes one less week of operations when compared to fiscal 2025. As Kevin indicated in his remarks, we intend to accelerate our technology roadmap to fundamentally improve how customers experience our brand, as well as allow for future benefits in both speed and cost efficiency. This incremental investment has not been factored into our fiscal 2026 outlook at this time. We will provide updated information once the scope, timing, and capital requirements of this project are finalized. Turning to inventory, inventory has increased 35 million or 48% to 107 million at the end of fiscal 25. Approximately 80% of the year-over-year increase was driven by initiatives to support significant growth opportunities at Rise Wellness and Haya. Let me break this down further. For Rise Wellness, the increase reflects the inventory necessary to support the launch and growth of Protein Pop, particularly retailers like Costco. For Haya, the inventory increase largely reflects channel expansion, including distribution into Target, international expansion into Canada and the United Kingdom, and building raw materials inventory in connection with USANA to begin manufacturing Haya products in-house. Given the growth trajectories of both RISE Wellness and Haya, we anticipate elevated inventory levels throughout fiscal 2026. Although we will continue to focus on working capital efficiency, our intention is to continue supporting product demand as well as the expansion of distribution channels and geographies for these important brands. We expect Rise Wellness to operate at approximately break-even in fiscal 2026, while we position the company for future growth, thoughtfully scale the business, and strengthen long-term revenue and profitability profile. Let me now touch on our effective income tax rate. Our effective tax rate guidance for fiscal 2026 is expected to range between 55% and 60%. The primary challenge we continue to face is a geographic misalignment between revenue generated and cost incurred. This dynamic has been particularly evident in our effective tax rate during the second half of fiscal 2025 and particularly felt with the recognition of certain one-time costs during the period. Execution of our growth strategy as well as targeted cost efficiencies are expected to contribute to a lower effective tax rate in future years. With that, I'll now turn the call back to Kevin before we open the line for questions.

Thanks, Doug. Let me close by saying this. We believe USANA is in a strong position, and the path ahead is both clear and compelling. Our core business has faced year-over-year sales declines, but we are seeing encouraging signs of stabilization as we take the right steps to return the business to growth. Hyatt and Rise Wellness broaden our market and bring new energy to the portfolio, while our strategic investments are strengthening the foundation that will support our next phase of expansion. And with a solid financial position, including a strong cash balance and an efficient model that generates healthy cash flow, we have the flexibility to invest thoughtfully, execute with confidence, and build long-term value. Put simply, we have the people, the products, and the financial strength to win, and we're committed to doing exactly that. This, we believe, will deliver sustainable value creation for our shareholders. I'll now turn the call back to the operator for Q&A.

Thank you. We'll now be conducting a question and answer session. If you'd like to ask a question at this time, please press star 1 from your telephone keypad and a confirmation tone to indicate your line is in the question queue. You may press star 2 if you'd like to withdraw your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, for our first question. Thank you. And the first question is from the line of Anthony Lebszinski with Sidonia Company. Please proceed with your questions.

Thank you, and good morning, everyone, and thanks for taking the questions. It's certainly nice to see the better-than-expected results for the fourth quarter, as well as the higher-than-expected EPS guidance for 26 as well. So, you know, as we look at the guidance for both revenue and EPS, obviously, you provided revenue guidance in January. But, you know, nevertheless, you know, they are pretty wide ranges. Can you just walk us through the different puts and takes as to what you would need to do to get to the top end of the guidance? Are you perhaps assuming a notable improvement in the macro environment? Maybe just kind of walk us through the different puts and takes for revenue and EPS guidance.

Yeah, so I think it's easier if we break it down by some of the kind of the key brands we talked about, Anthony. And so with Rise Wellness, they're really on an emerging path. There's some of these orders we have in our back pocket, and some are banking on having orders in the back half the year. And so as we look at Rise, that's kind of the range that we provided specifically on the sales there. Haya is just very, very newly into Canada and will soon be in the UK and then launching Target here in April. So there's a lot of activity on the horizon there to go back and bridge that. I think in short, when we look at the revenue kind of equation and kind of the margin profile, I think achieving the top line is going to be the main thing that will help us go back and deliver the top end of the EPS.

Yeah, and hey, we have Walter here. Walter, will you just give some color to what Doug said? Walter is on the management team that's in the trenches day-to-day on some of these things, and I thought I might bring you some added color to hear from Walter on this subject.

Yeah, as what Doug was saying, we've booked a lot of business on the retail side, but when you look at the inventory buildup, most of that inventory buildup is already committed revenue, which we've had through these retailers. We've got Target. We're in all the Target stores in the U.S. We're in all the Costco stores now as of last week, and then we've got other major U.S. retailers that we're talking to right now. So that's really, as we move forward, we're adding more flavors to the protein pop line that's going to go into Target, and then, of course, all the new retailers that are coming in. So we just see a huge upside, a huge potential for us, but, again, that's why we put such a big range on the guidance. And with Haya, we're super excited. What we've seen so far in Canada has been really good. We just barely launched that. Probably in the next couple of weeks, next three weeks, we're going to see the UK go live. In April, you see Target go live. On the retail side, that's a stand-up that goes into every store. So we're pretty bullish on both these businesses and the growth of these businesses. And a lot of it's just because there's such a range. I mean, the reason the range is there is because you don't know exactly what you're going to do, but High has been such a great brand. The company has spent so much money on marketing and creating so much awareness in the U.S. We think the retail channel is going to be really good for us.

You know, and one of the things that I'm sure of which you all are aware is that the omni-channel strategy is also a diversification of revenue strategy, meaning the more these succeed and we're generating money so it's not disproportionate to China and more locally based, that will help our effective tax rate where we're generating income, which is part of our also long-term strategy just to diversify where revenue is being generated because, as you can see from what hit us this last quarter, it's pretty significant. And so that's a very real opportunity for us.

Yeah, and maybe, Anthony, to kind of go full circle on this, we're still very bullish on our core nutritional business. And there's so many opportunities. I think Kevin's initiative to go back and look at technology and advance some of those roadmaps and really support that team. But I think we're at a time where people want health and wellness products, and we make as good as products as you can find out there, and so we really see these things as enablers moving forward.

Gotcha. Yeah. Thanks for all that color. So as we look to update our models here, is there anything that you guys can say as far as, I mean, obviously you will have one less week of sales in the fourth quarter. So I realize that. But other than that, I mean, for as we look at the business quarter one to two, three and four, I mean, is there anything anything to keep in mind as far as, you know, will the, you know, revenue ramp up as the year progresses? Or do we think that it should be more kind of, you know, even throughout the throughout the year? Anything to point out to as far as the seasonality of the business?

So seasonality, I think particularly in our core nutrition business, has really, as we evolved and grown in China, has revolved around that Lunar New Year, and it's fairly impactful. And so that market, as well as many of our markets in the Asia-Pacific region, really set up a pretty heavy promotional cadence surrounding that to support the business as we go through there. And so I would say the activity that we see quarter to quarter isn't perfectly equal, and so you'll see some ebbs and flows, which we can just give color as the year progresses.

Yeah, and we have Brent Neidig here at the table, who is our chief commercial officer, that also could add some color to what we're seeing from the revenue base as it relates specifically to our core nutritional business.

Yeah, thanks, Kevin. Doug just highlighted there is a certain element of seasonality in our core nutritional business, especially with our predominance within the Chinese community. We're currently in Chinese New Year right now, and typically leading up to that New Year in many of our Chinese markets, specifically in mainland China, there is a heavier emphasis on promotional activity as many of our brand partners want to stock up on product to provide for gifts and other selling opportunities throughout the Chinese New Year. That's why we typically see a stronger Q1. And then that momentum starts to escalate into Q2 as well as we have different conventions and events that kick off both in our first quarter and our second quarter. As we hit Q3, summer season, and a lot of our brand partners typically take time off or they go on vacation. They spend time with family as their kids are out of school. So we typically see a lull there. That's what we're expecting. That's what I'm continuing to expect. And then Q4, people start to get back into action and prepare for the following year. So that's typically the model that I see.

Gotcha. And then as it relates to Haya and then Rise, any added color there that you can share?

This is Walter. I don't know how much color I can share. When I look at that business, of course, it's a growing trend. And protein, especially protein pop, there's a really strong trend there. And we basically introduced, man, late last year, we really introduced protein pop retail. So it's a very new brand, and it's building. And as that brand continues to build, I think we'll continue to see it grow in the retail channel. I don't know exactly what the numbers are going to look like, but we've put some guidance in place. And we're feeling really good about where we're going.

Gotcha. And so, and it sounds like you also feel good about Haya as well. So, you know, as far as, you know, the cost realignment that you guys did in the fourth quarter, can you just help us out as far as, you know, how much that, you know, lowered your headcount? And then I know you're using some of those cost savings for other things as well. But maybe just you could also touch on how to think about gross margins here for 26 as well as your SG&A. Any sort of added color there would be certainly appreciated.

Yeah, Anthony. So the total was about 10% of the workforce that was impacted in that cost realignment. You know, overall, on a net basis, after some of the money's been repurposed, we're probably about $10 million or so in savings, maybe $10 plus in that range. I think a lot of the things these are being repurposed to are very important to the business and executing strategy and stabilizing. But that's, you know, those would primarily reside in SG&A. I would expect a whole lot in gross margin or cost of sales. The primary issue you're going to see on a few of our key line items is the mix between the different businesses. right? And so as you see RISE grow, and right now we talked about them being break-even this year, they're going to be at a little bit, they'll be at a much thinner gross margin. And so that'll kind of, you know, give the impression, but we'll break that out accordingly. So you have some optics there as we move forward into the year as well.

Gotcha. Okay. And then you touched on some of the, you mentioned technology initiatives that you're working on. I know you're not ready to share specifics. It sounds like it's still something that you're working on, but can you give us a sneak peek as to what you're thinking as far as how impactful that could be as far as some of the changes that you're looking to do on the technology side?

Well, this is Kevin. From my perspective, the notion of staying relevant in today's world is so important for us. And how people interact with our brand and or brands is very critical and will determine the future growth of our company, I believe. And so I want to focus on the ability to be quick and be nimble. And our traditional approach has been where we build things in-house, and that has served us very well. Strategically, we're going to look at how can we leverage outside resources in a more robust way both in the US as well as internationally but I think speed to market and speed to change and the relevance of how people interact will be a big part of the focus of the strategy behind our technology spend which will allow people to interact in a much more robust way with our brand and our brands across the board the other thing we're going to do which we haven't really spoken much about is we're going to leverage the knowledge and expertise for instance Haya they have a great knowledge and expertise in brand awareness and so how can we utilize some of their expertise and resources to help us leverage the USANA brand and and the USANA brand awareness. And so as we move forward, that's very kind of high-level fluff and not real detail, but I am convinced that if we can leverage especially AI in a way that we see many, many really high-end brands interact and utilize AI, which we aren't to its fullest capacity right now and it's changing literally every day and we have to play in that space and be as good at technology and utilizing ai as we are in nutrition is the goal i think that's the future of a growth company in our space one of the things i'm most excited about is if you look at the i've seen numbers uh a global kegger of about anywhere from 5% to 8% growth in the health and wellness space. Well, that's where we play. We should be on those curves as a company, and technology plays a key role in that growth. So that's where my head's at.

That's a very helpful caller. Well, thank you very much, and best of luck.

Thank you.

The next question comes in the line of Ivan Feinseth with Tigris Financial. Pleasure to see you with your questions.

Thanks for taking my question, and congratulations on the ongoing success of HIA and the new Rise Bars, which I sampled at the ICR conference and were really delicious and subsequently have purchased them. So I think that's really great. Going to the technology question for Kevin, what are your focus and thoughts on integrating technology into the consumer health management journey? Recently, another company launched a product that can give you a nutritional absorption reading through your finger. And when I was at the ISAR conference with Doug and Andrew and Patrick, we were talking about the monitor from Kohler. And, you know, what gets measured gets managed, and the more technology that a consumer can use to give insight to their health and nutrition journey, the more they can see, you know, where they need products or creating product opportunities for your company.

So, Ivan, thanks for the question. That's a great question. I am highly interested in the utilization of technology and the ability to personalize how a person receives their nutrition and not have it based on a one-size-fits-all approach and moving further into the technology space. I have our chief science officer here with us, Catherine Armstrong. Catherine, do you want to jump in on this real quick with this conversation with Ivan?

Hi, Ivan. It's good to talk to you again.

You too.

So I think for us, you know, we have obviously a focus on integrity and ensuring that everything we provide to our customers through all of our brands meets scientific rigor. And I know all of us have watched with eager anticipation over the past decade and more as these types of devices have been launched and then, you know, really struggled to link to clinical efficacy. And it's a lot about behavioral science versus physiological science, as you know. So are we actively looking at how to help individuals personalize and monitor their health status? Of course, we will continue to do so. And we are partnering to better understand how to advance that in a way that has scientific integrity and ensures our customers are able to apply their spend to true physiological benefits.

All right. Thank you.

Thanks, Ivan.

Thank you. As a reminder, if you'd like to ask a question at this time, you may press star 1 from your telephone keypad. We'll pause a moment to assemble the queue. Thank you. At this time, this will conclude our question and answer session. I'll turn the floor back to Andrew Masuda for closing comments.

Thanks for your questions and participation on today's conference call. If you have any remaining questions, please feel free to contact Investor Relations at 801-954-7210.

Ladies and gentlemen, this does conclude today's conference. Let me disconnect your lines at this time and have a wonderful day.